Trial
NCT03905343
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
The Belgian Society of Medical Oncology
Condition
Breast Cancer
Intervention
Ribociclib
Why stopped
Feasibility (low patient accrual and financial reasons)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-16